The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage

BMC Musculoskeletal Disorders

Volumn 12, Issue , 2011, Pages

  Stradner, Martin H ^a   Angerer, Hannes ^a   Ortner, Thomas ^a   Fuerst, Florentine C ^a   Setznagl, Daniela ^a   Kremser, Marie Luise ^a   Hermann, Josef ^a   Graninger, Winfried B ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

chondrocyte; fingolimod; FTY720; glycosaminoglycan; inducible nitric oxide synthase; interleukin 1; tumor necrosis factor

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; COLLAGENASE 3; CYCLOOXYGENASE 2; FINGOLIMOD; GLYCOSAMINOGLYCAN; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1BETA; INTERSTITIAL COLLAGENASE; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA; DRUG DERIVATIVE; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ANIMAL CELL; ARTICLE; ARTICULAR CARTILAGE; CARTILAGE CELL; CARTILAGE DEGENERATION; COW; DRUG MECHANISM; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CATTLE; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CARTILAGE, ARTICULAR; CATTLE; CELLS, CULTURED; CHONDROCYTES; GLYCOSAMINOGLYCANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-1BETA; MATRIX METALLOPROTEINASE 13; MATRIX METALLOPROTEINASE 3; NITRIC OXIDE SYNTHASE TYPE II; PROPYLENE GLYCOLS; SPHINGOSINE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 83155163778     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-12-279     Document Type: Article

References (27)

1. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Tedesco-Silva H, Szakaly P, Shoker A, Sommerer C, Yoshimura N, Schena FP, Cremer M, Hmissi A, Mayer H, Lang P, Transplantation 2007 84 885 892 10.1097/01.tp.0000281385.26500.3b 17984842 (Pubitemid 351338950)
2. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. Kappos L, Radue EW, O'Connor P, Polman C, Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M, Zhang-Auberson L, et al. N Engl J Med 362 387 401
3. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G, et al. N Engl J Med 362 402 415
4. FTY720: dissection of membrane receptor-operated, stereospecific effects on cell migration from receptor-independent antiproliferative and apoptotic effects. Brinkmann V, Wilt C, Kristofic C, Nikolova Z, Hof RP, Chen S, Albert R, Cottens S, Transplant Proc 2001 33 3078 3080 10.1016/S0041-1345(01)02312-0 11750323 (Pubitemid 34042491)
5. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Takabe K, Paugh S, Milstien S, Spiegel S, Pharmacol Rev 2008 60 181 195 10.1124/pr.107.07113 18552276 (Pubitemid 351962008)
6. The immunosuppressant FTY720 down-regulates sphingosine 1-phosphate G protein-coupled receptors. Graler MH, Goetzl EJ, FASEB J 2004 18 551 553 14715694
7. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Matloubian M, Lo CG, Cinamon G, Lesneski MJ, Xu Y, Brinkmann V, Allende ML, Proia RL, Cyster JG, Nature 2004 427 355 360 10.1038/nature02284 14737169 (Pubitemid 38133663)
8. S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis. Kikuta J, Iwai K, Saeki Y, Ishii M, Rheumatol Int 2010 31 967 9 21113810
9. Reduction of CD4 positive T cells and improvement of pathological changes of collagen-induced arthritis by FTY720. Wang F, Tan W, Guo D, He S, Eur J Pharmacol 2007 573 230 240 10.1016/j.ejphar.2007.07.029 17716652 (Pubitemid 47464222)
10. Effect of FTY720, a novel immunosuppressant, on adjuvant- and collagen-induced arthritis in rats. Matsuura M, Imayoshi T, Okumoto T, Int J Immunopharmacol 2000 22 323 331 10.1016/S0192-0561(99)00088-0 10689105 (Pubitemid 30109509)
11. Spingosine-1-phosphate stimulates proliferation and counteracts interleukin-1 induced nitric oxide formation in articular chondrocytes. Stradner MH, Hermann J, Angerer H, Setznagl D, Sunk IG, Windhager R, Graninger WB, Osteoarthritis Cartilage 2008 16 305 311 10.1016/j.joca.2007.06.018 17703957 (Pubitemid 351309177)
12. Sphingosine-1-phosphate stimulates rat primary chondrocyte proliferation. Kim MK, Lee HY, Kwak JY, Park JI, Yun J, Bae YS, Biochem Biophys Res Commun 2006 345 67 73 10.1016/j.bbrc.2006.04.042 16674917
13. Sphingosine-1-phosphate attenuates proteoglycan aggrecan expression via production of prostaglandin E2 from human articular chondrocytes. Masuko K, Murata M, Nakamura H, Yudoh K, Nishioka K, Kato T, BMC Musculoskeletal Disorders 2007 8 29 10.1186/1471-2474-8-29 17374154 (Pubitemid 46537414)
14. Primer3 on the WWW for general users and for biologist programmers. http://frodo.wi.mit.edu/cgi-bin/primer3/primer3-www.cgi
15. MIQE précis: Practical implementation of minimum standard guidelines for fluorescence-based quantitative real-time PCR experiments. Bustin SA, Beaulieu JF, Huggett J, Jaggi R, Kibenge FS, Olsvik PA, Penning LC, Toegel S, BMC Mol Biol 2010 11 74 10.1186/1471-2199-11-74 20858237
16. A Direct Spectrophotometric Microassay for Sulfated Glucosaminoglycans in Cartilage Cultures. Richard W, Farndale CAS, Barrett Alan J, Connective Tissue Research 1982 9 247 248 10.3109/03008208209160269 6215207 (Pubitemid 12009669)
17. Limitations of safranin 'O' staining in proteoglycan-depleted cartilage demonstrated with monoclonal antibodies. Camplejohn KL, Allard SA, Histochemistry 1988 89 185 188 10.1007/BF00489922 3135283
18. Effects of the novel immunosuppressant FTY720 in a murine rheumatoid arthritis model. Tsunemi S, Iwasaki T, Kitano S, Imado T, Miyazawa K, Sano H, Clin Immunol 2010 136 197 204 10.1016/j.clim.2010.03.428 20421177
19. Development of proteoglycan-induced arthritis depends on T cell-supported autoantibody production, but does not involve significant influx of T cells into the joints. Angyal A, Egelston C, Kobezda T, Olasz K, Lászlá A, Glant T, Mikecz K, Arthritis Res Ther 2010 12 44 10.1186/ar2954 20298547
20. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, Bruns C, Prieschl E, Baumruker T, Hiestand P, et al. J Biol Chem 2002 277 21453 21457 10.1074/jbc.C200176200 11967257 (Pubitemid 34952287)
21. Sphingosine 1-Phosphate Cross-activates the Smad Signaling Cascade and Mimics Transforming Growth Factor-{beta}-induced Cell Responses. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, Schafer-Korting M, Pfeilschifter J, Huwiler A, J Biol Chem 2004 279 35255 35262 10.1074/jbc.M312091200 15192102 (Pubitemid 39100522)
22. Activation of stress-activated protein kinase in osteoarthritic cartilage: evidence for nitric oxide dependence. Clancy R, Rediske J, Koehne C, Stoyanovsky D, Amin A, Attur M, Iyama K, Abramson SB, Osteoarthritis and Cartilage 2001 9 294 10.1053/joca.2000.0388 11399092 (Pubitemid 32454772)
23. Chondrocyte apoptosis induced by nitric oxide. Blanco FJ, Ochs RL, Schwarz H, Lotz M, Am J Pathol 1995 146 75 85 7856740
24. Effect of Interleukin-1 and Leukemia Inhibitory Factor on Chondrocyte Metabolism in Articular Cartilage from Normal and Interleukin-6-deficient Mice: Role of Nitric Oxide and IL-6 in the Suppression of Proteoglycan Synthesis. Van de Loo FAJ, Arntz OJ, Van Den Berg WB, Cytokine 1997 9 453 10.1006/cyto.1997. 0188 9237807 (Pubitemid 27312246)
25. Nitric oxide inhibits the synthesis of type-II collagen without altering Col2A1 mRNA abundance: prolyl hydroxylase as a possible target. Cao M, Westerhausen-Larson A, Niyibizi CKK, Georgescu HI, Rizzo CF, Hebda PA, Stefanovic-Racic M, CH E, Biochem J 1997 Pt 1 305 310 (Pubitemid 27229397)
26. Animal models of arthritis in NOS2-deficient mice. van den Berg WB, van de Loo F, Joosten LAB, Arntz OJ, Osteoarthritis and Cartilage 1999 7 413 10.1053/joca.1999.0228 10419784 (Pubitemid 29331565)
27. Preparation of antibodies against a novel immunosuppressant, FTY720, and development of an enzyme immunoassay for FTY720. Matsumoto N, Kohno T, Uchida S, Shimizu T, Kusumoto H, Hirose R, Yanada K, Kurio W, Yamaguchi S, Watabe K, et al. Bioorg Med Chem 2006 14 4182 4192 10.1016/j.bmc.2006.01.071 16504516